Coromandel International Ltd.
Chemicals · NSE
52-week range
₹1,818 – ₹2,708
From 52w high
-28.8%
RSI (14)
38.0
vs SMA 50 / 200
↓ 50 · ↓ 200
Coromandel International (Chemicals sector) trades at ₹1,927.60, down 14.95% over the past 12 months and 28.82% from its 52-week high, with price below both the 50-DMA (₹2,040.51) and 200-DMA (₹2,228.14). Q4 FY26 net profit fell approximately 80% to ₹115 crore despite full-year revenue growth of approximately 30%, while the 5-year earnings CAGR stands at -75.8% against a 5-year revenue CAGR of 20.4%. Debt-to-equity is elevated at 11.47 with a rising debt trend, and the quality score of 30 ranks 4th of 6 among Chemicals peers.
- ✓5-year revenue CAGR of 20.4% demonstrates consistent topline expansion even as margins have been pressured.
- ✓PE of 29.09 is the lowest among the 6-peer Chemicals group (peers range from 30.79 to 100.09), reflecting a significant valuation discount relative to sector comparables.
- ✓ROE of 15.59% ranks 2nd of the 4 peers for which ROE data is available, with 4 years above the 15% threshold in the available persistence window.
- ✓Nano fertiliser business has been described in recent company disclosures as attaining market leadership, representing a potential differentiation within the agri-inputs segment.
- ✗Q4 FY26 net profit fell approximately 80% YoY and the 5-year earnings CAGR is -75.8%, indicating that revenue growth has not compounded into earnings over the medium term.
- ✗Debt-to-equity of 11.47 is elevated within the Chemicals sector context, with a rising debt trend flagged — a combination that increases financial risk if earnings remain depressed.
- ✗FCF was positive in only 3 of the available historical years and the consistency score stands at 48, reflecting irregular free cash flow generation.
- ✗Quality score of 30 ranks 4th of 6 peers and the stock has traded below its 200-DMA for an extended period with a 28.82% drawdown from the 52-week high and a 15.24% decline over the past 3 months.
- ·Q4 FY26 results (reported May 7-8, 2026) showed revenue growth of approximately 20-30% alongside a net profit decline of approximately 80% to ₹115 crore, attributed to a surge in expenses; the stock fell approximately 3% on the results day.
- ·FY26 full-year revenue was reported up 30% and the nano fertiliser business was described by the company as achieving market leadership, providing a counter-narrative to the quarterly profit decline.
- ·Mean analyst rating of 1.67 across 9 analysts (1-5 scale, lower = more constructive) reflects coverage that is relatively concentrated at the constructive end of the scale, though the sample of 9 analysts is thin.
- ?Is the Q4 expense surge a one-time item (as CNBC TV18 reported management attributed it to one-offs), or does it reflect a structural shift in the cost base that could persist into FY27?
- ?Given a debt-to-equity of 11.47 with a rising trend, how does the company plan to manage its debt obligations if agri-input commodity cycles compress margins further?
- ?The nano fertiliser segment is described as a market leader — how large is this segment as a proportion of total revenue, and what is its margin profile relative to the legacy business?
- ?Does the 5-year revenue CAGR of 20.4% alongside a -75.8% earnings CAGR reflect a structural margin compression in the agri-chemicals business, or is it largely explained by one or two outlier years?
PE
29.1
Forward PE
18.0
ROE
+15.6%
Profit margin
+6.2%
D/E
11.47
Dividend yield
+0.6%
Quality score
30/100
ROE 5y above 15%
4/5 yrs
FCF 5y positive
3/5 yrs
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.Analysis generated 11 May 2026.